🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Roche stock down 5% after disappointing drug trial data update

Published 11/09/2024, 18:26
© Reuters.
RHHBY
-

Roche (RHHBY (OTC:RHHBY)) shares dropped 5.4% on Wednesday following an update about the early-stage trial of its weight-loss pill, CT-996.

The Swiss pharmaceutical giant said in July that the experimental pill resulted in a 6.1% placebo-adjusted weight loss over four weeks in a Phase I trial, creating optimism around its potential.

However, recent details show the reported results came from a subgroup of only six participants, with the news disappointing investors, sending Roche shares lower on Wednesday.

Presentation slides published on Wednesday demonstrate that while the Phase I trial involved 25 participants in total, only six of them were given a placebo for comparison, and the 6.1% weight loss figure came from the best-performing of three treatment subgroups.

The second-best-performing subgroup had seven volunteers and is said to have achieved a lower placebo-adjusted weight loss of 4.6%.

Roche noted that larger, more rigorous trials will commence next year to gather more definitive data.

The company defended the trial's design, explaining that doses were ramped up more quickly than planned for future trials to identify any potential side effects early on.

Roche's acquisition of CT-996's developer, Carmot, for $2.7 billion in December signaled its ambition to compete in the lucrative weight-loss drug market, which analysts predict could reach $150 billion by the early 2030s.

Meanwhile, competitors Novo Nordisk and Eli Lilly saw their stocks rise by 4.3% and 2%, respectively, further benefiting from their leadership positions in the weight-loss market.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.